Collexis and SyynX Preview Next Generation Scientific Network

Collexis (OTCBB: CLXS), a leading developer of high-definition
search and discovery software, and their German partner, SyynX
Solutions, today announced they will preview a new life sciences
social networking site to representatives from global book publishing
and multimedia companies at the Frankfurt Book Fair in Frankfurt,
Germany, from Wednesday, October 10, 2007 to Friday, October 12, 2007.
This online community represents the next generation in social
networks. The comprehensive system of pre-populated expert profiles,
coupled with the ability to analyze all associated professional
connections within the network, allows scientists and researchers
across multiple organizations to share data and collaborate in ways
never before considered.

Over the next few weeks, a controlled group of research thought
leaders are testing the site for a public launch slated for January,
when the site's name and web address will be formally released to the
public. However, Frankfurt Book Fair attendees can gain access to the
site at the companies' joint booth, number 417 in Hall 4.2, at any
time during the conference, or during a wine and cheese reception on
Thursday, October 9, from 4 p.m. to 6 p.m.

Designed to promote collaborative research and development in
advancing medical science, the site is the first social networking
application to incorporate pre-generated expert profiles of over 1.4
million biomedical experts from more than 150 countries. It currently
houses approximately 12 million pre-established network connections,
automatically generated from over six million scientific publications
from 6,500 journals. Contrary to the first generation social networks
like Facebook and LinkedIn, this life science open platform goes to
the next level and reflects the real-life activity network of the
experts worldwide.

"Social networking isn't just for teenagers. There are a growing
number of academics who are finding that online communities are the
perfect way to share, collaborate and discuss their work," said Bill
Kirkland, Collexis CEO. "But until now, an efficient way to coordinate
the abundance of available digital information did not exist. The
technology behind our site now makes it possible for researchers to
collaborate in a way not previously possible."

"When a researcher logs into the site, available at no-charge,
they will immediately see a robust synopsis of their publications,
interests and network," added Kirkland. "The depth of this
information, encompassing almost every published researcher in the
biomedical sciences field worldwide, is what makes the site incredibly
powerful. It also serves as a definitive source to identify
relationships to others within the community, either by topic or
geography."

The social networking site is based on Collexis' proprietary
Fingerprint technology, a valuable research tool already employed by
organizations such as: Johns Hopkins, The Mayo Clinic, Harvard
University and The National Institute of Health.

"Taking the Collexis technology, which has become the platform of
choice for leading biomedical companies, and combining it with a free
social network application was really the next logical step," said
Christian Herzog, MD, CEO of SyynX Solutions. "Thanks to the genius of
Martin Schmidt, our chief technology officer, in collaboration with
the Collexis leadership, the research community will now be able to
instantaneously identify relevant expertise in a specific research
area and start collaborating directly. Plus, we see the next
generations of this platform expanding beyond biomedical research and
into larger, global R&D development efforts."

About Collexis Holdings, Inc.

Collexis Holdings, Inc., a leading developer of High Definition
Search and Discovery software since 1999, is headquartered in
Columbia, South Carolina (USA) with two subsidiaries; Collexis Inc. in
Columbia, South Carolina, USA and Collexis, B.V. in Geldermalsen, The
Netherlands. Collexis proprietary technology builds conceptual
profiles of text, called Fingerprints, from documents, websites,
e-mails and other digitized content and matches them with a
comprehensive list of pre-defined "fingerprinted" concepts to make
research results more relevant and efficient. This matching of
concepts eliminates the ambiguity and lack of priority associated with
word searches. The results are often described as "finding needles in
many haystacks." Through this novel approach, Collexis can build
unique applications to search, index and aggregate information as well
as prioritize, trend and predict data based on sources in multiple
industries without the limitations of language or dialect. Collexis
shares of common stock are traded under the symbol CLXS on the OTC
Bulletin Board (OTC BB). For more information, please visit
www.collexis.com.

About SyynX Solutions GmbH

SyynX Solutions GmbH

SyynX Solutions GmbH is a German software company which focuses on
text mining based applications for the areas of life science and
health care. Collexis and SyynX are already co-operating closely since
almost ten years on the technical and commercial level. The SyynX
applications based on the Collexis fingerprint technology are used by
customers like universities, pharmaceutical and biotech companies
around the world. The text mining applications like the SyynX
Knowledge Dashboard helps the user to analyze large text corpora
without applying standard search approaches and provides him
automatically with expert profiles, trends and knowledge discovery
routines. For more information please visit www.syynx.de.

This press release contains forward-looking statements. Such
statements are valid only as of today, and we disclaim any obligation
to update this information. These statements are subject to known and
unknown risks and uncertainties that may cause actual future
experience and results to differ materially from the statements made.
These statements are based on our current beliefs and expectations as
to future outcomes. Factors that could affect future performance
include business and economic trends, the ability to continue funding
operating losses, fluctuations in operating results, continued success
in developing our research software and other risk factors as
disclosed in our public filings with the Securities and Exchange
Commission.